Drug Topics
MAY 1, 2024
According to Michael Osso, president and chief executive officer of the Crohn’s & Colitis Foundation, “the flexibility of having multiple biosimilar formulations to choose from is important to support broader patient access to biologic medicine.
PharmaVoice
MAY 1, 2024
The FDA’s newly launched Center for Clinical Trial Innovation potentially opens the door for more efficient and expanded AI use, but leaves pharmas wanting more guidance.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
MAY 1, 2024
Savings associated with biosimilar uptake are projected to reach $181 billion through 2027.
STAT
MAY 1, 2024
Extensive testing of pasteurized commercially purchased milk and other dairy products from 38 states has found no evidence of live H5N1 bird flu virus, Food and Drug Administration officials said at a press briefing Wednesday. The results confirmed findings of earlier testing of a more limited number of samples and add weight to the FDA’s conclusion that pasteurized milk products are safe for consumption despite a widespread outbreak of cows infected with H5N1.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
MAY 1, 2024
One notable incentive includes the launch of biosimilars at both low- and high wholesale acquisition costs.
Pharmaceutical Technology
MAY 1, 2024
AstraZeneca has maintained that while the vaccine may, in “very rare” cases, cause TTS, the casual mechanism for this effect remains unknown.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
MAY 1, 2024
When Maureen Amirault purchased her first electric wheelchair in 2020, she had been living with muscular dystrophy for decades. Braces and a cane helped, but walking became too arduous, so she got a chair through a company called Numotion. The first few months were great. The headrest fell off, but Numotion fixed it in a matter of days.
Drug Topics
MAY 1, 2024
Although the US Drug Enforcement Agency's (DEA) proposed reclassification of marijuana wouldn’t legalize the drug nationwide, it could shake up the current marijuana landscape.
STAT
MAY 1, 2024
NEW YORK — By the time Peter Bauman considered deep brain stimulation, he was desperate. Early onset Parkinson’s disease, diagnosed at age 49, had disabled him, ended his bartending career, and led him to consider suicide. He hoped that the treatment, known as DBS, in which an electrode connected to an external battery is inserted into the brain and emits electrical impulses, would ease his Parkinson’s tremors.
Drug Topics
MAY 1, 2024
Pharmacists can help financial decision makers understand the value of biosimilar therapies.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
MAY 1, 2024
WASHINGTON — A House panel is pushing for a virus research group and its director to be barred from any federal funds and criminally investigated, the latest in a campaign to probe the origins of the Covid-19 pandemic and regulate virus research. Republicans, in particular, are asking the administration to immediately debar the research group EcoHealth Alliance, and to refer the case to law enforcement.
Drug Topics
MAY 1, 2024
In a testimony to the Senate Finance Committee, Andrew Witty discussed what led to the February Change Healthcare cyberattack and the organization’s response.
Pharmacy Times
MAY 1, 2024
The 1-time treatment may be a better alternative for patients who don’t want to undergo frequent doses of standard of care intravenous factor IX infusions.
STAT
MAY 1, 2024
On Wednesday, UnitedHealth CEO Andrew Witty appeared before Congress to answer for what lawmakers called a “single attack [that] kicked off a cascading series of crises that are unmasking some deep vulnerabilities in the core of our health care system”: the February Change Healthcare cyberattack that is still disrupting payment processing across the country.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fierce Healthcare
MAY 1, 2024
The scale of UnitedHealth Group's sprawling empire was under the microscope on Wednesday as CEO Andrew Witty testified before a key Senate panel about the cyberattack on Change Healthcare that's ha | The scale of UnitedHealth Group's sprawling empire was under the microscope on Wednesday as CEO Andrew Witty testified before a key Senate panel about the cyberattack on Change Healthcare that's had ripple effects across healthcare.
pharmaphorum
MAY 1, 2024
Discover how digital tools can provide insights to help us. Digital technology could be a game-changer that offers the elusive promise of tackling the root cause, not just the conditions themselves, when it comes to human health.
Fierce Healthcare
MAY 1, 2024
The latest batch of Hospital Safety Grades from independent watchdog The Leapfrog Group suggest that patients’ care experiences, which deteriorated during and since the pandemic, may finally be tur | New data from the watchdog reflecting CMS-reported patient safety measures show that hospitals are, on average, working their way back from patient experience and hospital-acquired infection scores that plummeted during the COVID-19 pandemic.
Pharmacy Times
MAY 1, 2024
Venture capital investments in women's health are growing, with innovation looking beyond traditional avenues.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Healthcare
MAY 1, 2024
A newly formed group of women’s health companies aims to tackle gaps in care, with a focus on improving outcomes while reducing costs. | A newly formed group of women’s health companies aims to tackle gaps in care, with a focus on improving outcomes while reducing costs.
STAT
MAY 1, 2024
Blood vessels in the legs or heart sustain considerable damage when they are narrowed by poor circulation from diabetes or blocked in a heart attack. To repair them, researchers have tried using grafts from other blood vessels or giving growth factors to stimulate new tissue, but those solutions often fall short. Scientists from Boston Children’s Hospital report Wednesday in Nature that they managed to boost blood vessel growth by enlisting mitochondria, organelles that power the cell, to
Pharmacy Times
MAY 1, 2024
The COVID-19 pandemic spring boarded the evolution of pharmacies toward establishing their position as sites of care.
STAT
MAY 1, 2024
WASHINGTON — The Drug Enforcement Administration is reversing a regulation that had been expected to create shortages of morphine and other opioid injectables, according to a DEA letter to drugmakers obtained by STAT. The DEA dictates the quantity of controlled substances that drug companies are allowed to make. Until this year, those quotas were set annually for Schedule II drugs, such as morphine and other injectable opioids that hospitals regularly use.
Fierce Healthcare
MAY 1, 2024
The Office for Civil Rights (OCR) announced an update to Section 504 of the Rehabilitation Act of 1973 Tuesday, fortifying support for Americans with disabilities. | HHS finalized a proposed rule from September, granting greater protections to individuals with disabilities. Secretary Xavier Becerra says the department is willing to help providers meet new standards.
pharmaphorum
MAY 1, 2024
Explore the challenges in weight loss treatments despite the billions spent on clinical trials for weight loss drugs. Discover why capacity remains a critical issue in the industry.
STAT
MAY 1, 2024
CVS Health got walloped at the outset of 2024 as older adults in its Medicare plans continue to get a lot more medical care than the company expected. CVS’ operating income fell by 34% — roughly $1.2 billion — in the first quarter compared with the prior-year period, according to results released Tuesday. The company, which absorbed the health insurer Aetna in 2018, marketed its Medicare Advantage plans aggressively last year and expanded its geographic reach more than any i
pharmaphorum
MAY 1, 2024
FTC sends more warnings to pharma companies over 'junk' patents to protect drugs from generic competition, including Novo Nordisk's Ozempic.
Fierce Healthcare
MAY 1, 2024
CVS Health is lowering its guidance for the year after a first-quarter miss on both profit and revenue. | The company posted $1.1 billion in profit for the quarter as well as $88.4 billion in revenue. Both fell short of Wall Street analysts' expectations, according to Zacks Investment Research.
pharmaphorum
MAY 1, 2024
Polish drug delivery company Biotts says it has demonstrated delivery of insulin across the skin for the first time without the use of an injection system.
The Guardian - Pharmaceutical Industry
MAY 1, 2024
Deal would resolve tens of thousands of lawsuits alleging company’s baby powder causes ovarian cancer Johnson & Johnson is moving forward with a $6.475bn proposed settlement of tens of thousands of lawsuits alleging that its baby powder and other talc products contain asbestos and cause ovarian cancer. The deal would allow it to resolve the lawsuits through a third bankruptcy filing of a subsidiary company.
pharmaphorum
MAY 1, 2024
China's Jacobio Pharma is preparing to file its KRAS inhibitor glecirasib for approval, saying it could offer a safety advantage over current drugs in the class
STAT
MAY 1, 2024
LONDON — In 2021, a team of Italian researchers reported that an experimental gene therapy they had developed seemed to be correcting the metabolic issues at the core of a rare genetic disease that left children unable to break down sugar molecules. There remained an open question, however, about whether the therapy could address a particularly debilitating manifestation of the disease, the severe skeletal deformities it caused.
pharmaphorum
MAY 1, 2024
The MHRA's regulatory sandbox for artificial intelligence as medical device technologies, AI-Airlock, will go live this spring, according to a new strategy document
Fierce Pharma
MAY 1, 2024
Following the lead of Eli Lilly, Pfizer will establish a direct-to-consumer service, selling some of its medicines online and avoiding industry middlemen. | Following the lead of Eli Lilly, Pfizer will establish a direct-to-consumer service, selling some of its medicines online and avoiding industry middlemen. The company plans to sell products such as its COVID treatment Paxlovid and a migraine nasal spray in this way, it told the Financial Times.
Expert insights. Personalized for you.
503 
Let's personalize your content